Genentech is letting go of 87 employees at its South San Francisco headquarters, the second round of layoffs at the Roche subsidiary this year.
All entries for: Oncology
July 24, 2025
Replimune
Negative Outlook
Woburn, MA
201-500 employees
We cannot be sure whether additional legislation related to the IRA will be issued or enacted, or what impact, if any, such changes will have on the profitability of any of our drug candidates, if approved for commercial use, in the future. There also may be future changes unrelated to the IRA that result in reductions in potential coverage and reimbursement levels for our product candidates, if approved and commercialized, and we cannot predict the scope of any future changes or the impact that those changes would have on our operations.
Disease Area: Oncology
Drug Type: Biologic, Small Molecule
July 21, 2025
GSK - Cambridge
Layoffs
Cambridge, MA
50,001+ employees
GSK is letting go of 150 employees in Cambridge, Massachusetts, according to a Worker Adjustment and Retraining Notification (WARN) Act notice. Endpoints News reported that the London-based company plans to move manufacturing of its pneumococcal vaccine asset that uses its multiple antigen presenting system (MAPS) technology from Cambridge to Marietta, Pennsylvania.
Disease Area: Antiviral, Immune Diseases, Multiple, Oncology, Respiratory Diseases
Drug Type: Biologic, Small Molecule
July 17, 2025
GSK
Layoffs
San Francisco, CA
50,001+ employees
London-based GSK is cutting its global research and development team by an unspecified number of people, Fierce Biotech reported July 15. A spokesperson told Fierce a “very limited number of positions will be impacted” across the company’s R&D workforce of more than 12,000 people.
Disease Area: Immune Diseases, Multiple, Oncology, Rare Diseases, Respiratory Diseases
Drug Type: Biologic, Small Molecule
July 14, 2025
Karyopharm Therapeutics
Layoffs
Newton, MA
201-500 employees
As it continues exploring options to extend its cash runway, which could include a merger or sale, Karyopharm Therapeutics is cutting about 20% of its workforce, according to a July 11 SEC filing. The Newton, Massachusetts–based commercial-stage pharma did not specify which locations the layoffs affect.
Disease Area: Hematology, Multiple, Oncology
Drug Type: Small Molecule
July 2, 2025
Oncternal Therapeutics
Company Closure
San Diego, CA
1-50 employees
San Diego-based Oncternal Therapeutics is closing shop. To oversee the wind-down process, the company will retain only one employee: Craig Jalbert, a principal of the accounting firm Verdolino & Lowey, P.C. He will act as Oncternal’s president, CEO, treasurer, secretary and sole member of its board of directors. All remaining executives, directors and employees of Oncternal have resigned, though it’s not immediately clear how many people will be directly affected by the company’s closure. In September 2024, the biotech downsized by 37%, corresponding to about 10 employees, including its Chief Medical Officer Salim Yazji.
Disease Area: Hematology, Multiple, Oncology
Drug Type: Biologic, Small Molecule
July 1, 2025
Bristol Myers Squibb - Lawrenceville
Layoffs
Lawrenceville, NJ
10,001-50,000 employees
Bristol Myers Squibb continues to aim its cost-cutting measures at Lawrenceville, New Jersey, laying off 68 employees there, according to a Worker Adjustment and Retraining Notification notice. The pharma has now let go of 1,223 people in Lawrenceville since April 2024, including 874 team members this year. The latest cuts will occur in multiple waves starting Sept. 25 and end Jan. 15, 2026. BMS has its headquarters and a location housing its commercialization and late-stage development teams in Lawrenceville. It was not immediately clear if the latest layoffs affect both sites.
Disease Area: Cardiology, Hematology, Immune Diseases, Multiple, Oncology
Drug Type: Biologic, Small Molecule
June 25, 2025
Discontinued Research, Layoffs
Roughly a month after sharing that it would cut about half of its workforce, Leap Therapeutics has announced it will axe 75% of its staff over the next two months. The Cambridge, Massachusetts–based biotech is also winding down research and development activities and exploring strategic options that could include a sale, according to a June 23 SEC filing. The latest cuts affect 75% of the workforce, according to the filing, and will be carried out over two phases: one on or about June 30 and the second on or about July 31. The first round will include the departure of Augustine Lawlor, chief operating officer, while the second will include the exit of Cyndi Sirard, chief medical officer. Based on Leap having 52 full-time employees as of Dec. 31, according to its annual report, and the cuts detailed in a May 13 SEC filing, the company could have fewer than 10 staffers once the layoffs are complete.
Disease Area: Immune Diseases, Multiple, Oncology
Drug Type: Biologic
June 16, 2025
Gilead Sciences - Oceanside
Layoffs
Oceanside, CA
10,001-50,000 employees
Gilead Sciences cut 36 employees in Oceanside, California, effective Aug. 15, according to a Worker Adjustment and Retraining Notification notice. The location supports clinical manufacturing and process development for the Foster City, California–based pharma and subsidiary Kite Pharma.
Disease Area: Antiviral, Chronic Disease, Multiple, Oncology
Drug Type: Biologic, Small Molecule
June 16, 2025
ImmunityBio
Layoffs
Woburn, MA
501-1,000 employees
The San Diego–based biotech is letting go of three employees at their Woburn, Massachusetts, effective from July 29 to Aug. 12, according to a Worker Adjustment and Retraining Notification notice.
Disease Area: Infectious Diseases, Multiple, Oncology
Drug Type: Biologic, Small Molecule